Novo's drug CagriSema has demonstrated a significant 25% weight loss effect in women, a promising result that could boost the company's prospects. This development is important as it may help revive investor confidence and improve the company's stock performance, which has been struggling. The success of CagriSema could position Novo as a strong player in the weight loss market, with potential for further growth and positive financial impact.
Novo Nordisk A/S (NVO) trades at USD 39.11 on Pluang as of Oct 22, 2026 02:41 WIB, down 0.61% in the past day. The stock has a market cap of $172.91 billion and a dividend yield of 4.57%, with an even split in Pluang order activity between buyers and sellers. This trading context highlights ongoing investor interest as Novo advances its weight loss drug CagriSema, which could influence future stock performance.
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Novo Nordisk's experimental obesity drug CagriSema demonstrated an average 25% weight loss among adult women after 68 weeks in a new analysis following a late-stage trial. The drug, combining semaglutide and cagrilintide, also showed significant weig...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
